RecruitingPhase 2NCT06529432

A Study of Bupivacaine Liposome Injection in the Treatment of Pain After Thoracoscopic Surgery

Efficacy, Safety and Pharmacokinetics of Bupivacaine Liposome Injection for Paravertebral Nerve Block in the Treatment of Postoperative Pain After Thoracoscopic Surgery: a Multicenter, Randomized, Double-blind, Dose-finding, Positive Control, Phase Ⅱ Clinical Trial

Sponsor

Jiangsu HengRui Medicine Co., Ltd.

Enrollment

96 participants

Start Date

Mar 3, 2026

Study Type

INTERVENTIONAL

Conditions

Local Analgesia Via Nerve Block

Summary

The objective of this study is to evaluate the efficacy, safety, and tolerability of bupivacaine liposomes for paravertebral nerve block in the treatment of thoracoscopic postoperative pain, and to evaluate the relevant human pharmacokinetics.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Bupivacaine Hydrochloride Injection and a drug called Bupivacaine Liposome Injection for people with local analgesia via nerve block. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGBupivacaine Liposome Injection

Bupivacaine Liposome Injection Low Dose or Moderate Dose or High Dose

DRUGBupivacaine Hydrochloride Injection

Bupivacaine Hydrochloride Injection Low Dose or Moderate Dose or High Dose

Locations(1)

Zhongshan Hospital Affiliated to Fudan University

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06529432